ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658 · clinicaltrials.gov ↗

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Axillary Metastases

Interventions

PROCEDURE: Targeted axillary dissection (TAD) by ICG
PROCEDURE: Targeted axillary dissection (TAD) by Blue patent

Sponsor

Hospital Universitari de Bellvitge